Trial · NCT07059338
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338, Phase 2, Not yet recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer. Trials, record NCT07059338. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07059338
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
- NCT number
- NCT07059338
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 34 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- HER2 Positive, Colorectal Cancer (CRC)
- Interventions
- Trastuzumab +Cetuximab β+Irinotecan
- First posted
- 2025-07-10
- Last updated
- 2025-07-10
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month progression-free-survival rates | 2 years | Progression-free survival defined as the time from randomization to documented disease progression according to RECIST or death from any cause. We computed the 6-month PFS rate based on the available follow-up data. |
| Secondary | Objective response rate | 2 years | defined as the percentage of patients with complete or partial response according to RECIST |
| Secondary | Disease control rate | 2 years | defined as the percentage of patients with CR + PR + SD according to RECIST |
| Secondary | overall survival | 3 years | defined as the time from randomization to death from any cause |
| Secondary | Incidence of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 3 years | Percentage of patients, experiencing a specific adverse event, according to National Cancer Institute Common Toxicity Criteria (version 5.0), during the induction and the maintenance phases of treatment. |
| Other | Treatment-emergent genetic variants analysis by ctDNA sequencing | 2 years | Longitudinal assessment of somatic mutation profiles in circulating tumor DNA (ctDNA) using next-generation sequencing (NGS) to correlate genetic variants (e.g., HER2/EGFR/RAS pathway alterations) with objective response rate (ORR) per RECIST 1.1 criteria. |
| Other | Baseline proteomic predictive biomarkers for treatment efficacy | 3 years | Quantitative proteomic profiling of baseline plasma and tissue samples to identify predictive biomarkers correlated with therapeutic response. |
| Other | Treatment-induced proteomic alterations | 3 years | Quantitative proteomic analysis of plasma and tissue samples to detect therapy-mediated changes in protein expression and phosphorylation patterns. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07059338
GET https://conductscience.org/api/trials/v1/NCT07059338/registered